Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

28.53USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$28.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
62,991
52-wk High
$33.26
52-wk Low
$14.00

Select another date:

Tue, Nov 14 2017

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​ Source text: (http://bit.ly/2fqe6ME) Further company coverage:

BRIEF-Audentes Therapeutics appoints Fulvio Mavilio to vice president scientific affairs, Europe

* Audentes Therapeutics announces appointment of Fulvio Mavilio, Ph.D. To vice president scientific affairs, Europe Source text for Eikon: Further company coverage:

Select another date: